Chronic Kidney Disease Patients Preserve Kidney Function With Robot-Assisted Partial Nephrectomy

Chronic kidney disease patients who received robot-assisted partial nephrectomy to treat kidney cancer have minimal loss of kidney function - a smaller amount even than patients with normal kidney function.

Chronic kidney disease patients who received robot-assisted partial nephrectomy to treat kidney cancer have minimal loss of kidney function - a smaller amount even than patients with normal kidney function.

This is according to researchers at Henry Ford Hospital's Vattikuti Urology Institute.

Safety of Nivolumab in Kidney Cancer Tested By Dartmouth Researchers
A poster on a phase I clinical trial of Nivolumab, being used in combination with other drugs in patients with metastatic renal cell carcinoma (mRCC) will be presented by researchers.

The study, which includes patient data from five U.S. medical centers, is the largest of its kind. The study is published online ahead of print in European Urology, the journal of the European Association of Urology.

"Our study supports robot-assisted partial nephrectomy as an alternative to open surgery for patients with chronic kidney disease because decreases in kidney function after the procedure appear minimal," says senior study author Craig Rogers, M.D., a Henry Ford urologist and robotic surgery specialist. "In addition, no patients developed end-stage kidney disease requiring long-term kidney dialysis.

"Chronic kidney disease is a growing public health concern. With robot-assisted partial nephrectomy (RPN), we can save kidneys and preserve kidney function in patients who need it most.

Many Benefits Offered By Robot-assisted Kidney Cancer Surgery
According to a study, robot-assisted surgery to remove kidney cancers has seen a rapid increase in use, and has both replaced and proven safer than laparoscopic procedures for the same purpose.

Traditionally, these patients required a large open incision and longer recovery," says Dr. Rogers.

"Our study shows that these patients can also receive the benefits of a minimally invasive robotic approach when performed by experienced surgeons, and they do well."

Clinical Trial Reveals That 'Pazopanib' Offers Better Quality-of-Life For Patients With Advanced Kidney Cancer
A large international clinical trial found that two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability.

All of the patients in the study underwent RPN, a minimally invasive surgical procedure to remove cancerous tumors from the kidney while sparing healthy tissue. All cases were performed by surgeons with extensive experience in the RPN operation.

Data was collected from nearly 1,200 patients who underwent RPN between 2007 and 2012. Outcomes of patients who had pre-existing chronic kidney disease with decreased kidney function before surgery were compared against those with normal kidney function. Kidney function was measured according to each patient's glomerular filtration rate, which estimates the overall performance of the intricate system of cleansing filters in the kidneys.

Robotic Ultrasound Gives Surgeon More Direct Control in Mapping and Removing Kidney Cancers: Research
The use of ultrasound to identify tumors during kidney cancer surgery is gaining acceptance.

Using a statistical device to account for differences among the patients, the researchers found that patients with chronic kidney disease had a lesser amount of decline in kidney function after RPN than those with normal kidney function, when measured at their first follow-up exam and later visits.

However, those with pre-existing chronic kidney disease had a higher risk of relatively low-grade surgical complications and a longer hospital stay.

Source-Eurekalert